Harold R. Collard, MD, FCCP

Assistant Clinical Professor of Medicine
Coordinator, Interstitial Lung Disease Program
Acting Director of Clinical Services
Division of Pulmonary and Critical Care Medicine
San Francisco General Hospital
University of California, San Francisco

Harold R. Collard, MD, FCCP is Assistant Clinical Professor of Medicine in the Division of Pulmonary and Critical Care Medicine and Coordinator of the Interstitial Lung Disease Program at the University of California, San Francisco. He is also the Acting Director of Clinical Services for the Division of Pulmonary and Critical Care Medicine at San Francisco General Hospital.

Dr. Collard received his undergraduate degree from Harvard College in Cambridge, Massachusetts, and his medical degree from Duke University in Durham, North Carolina. He completed his internship, residency, and chief residency in Internal Medicine at UCSF, and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado in Denver. Prior to joining the faculty at UCSF, he was a staff physician at National Jewish Medical and Research Center in Denver and a member of the Interstitial Lung Disease Program there.

Dr. Collard’s clinical and research specialty is the care of patients with interstitial lung disease. His research interests focus on questions surrounding the management of patients with ILD, including how best to diagnose and treat these conditions and how an ILD diagnosis affects patient quality of life and survival.

Disclosure Statement

The France Foundation relies upon faculty members to provide educational information in a manner that is objective and free from bias. In compliance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Commercial Support, all faculty members are required to disclose any conflicts of interest related to the context of their participation in a CME activity. Faculty members have disclosed the following relationships with commercial interests:

Harold R. Collard, MD, has served as a consultant for CV Therapeutics, Genzyme, Gilead, and InterMune.